OSE Immunotherapeutics Proposes Governance Evolution and Reaffirms Strategic Priorities ahead of Annual General Meeting

OSE Immunotherapeutics Proposes Governance Evolution and Reaffirms Strategic Priorities ahead of Annual General Meeting

New Board Structure Reflects Balanced and Proportionate Shareholder Representation
New Governance to Drive Strategic Roadmaps for Tedopi® and Lusvertikimab